Table 1 Demographic characteristics of the study participants.
Overall | Pfizer N = 110 | Moderna N = 89 | AstraZeneca N = 131 | Sinopharm N = 122 | |
|---|---|---|---|---|---|
Age | 38.1 ± 12.8 | 31.8 ± 8.13 | 36.1 ± 10.9 | 50.2 ± 12.4 | 32.2 ± 8.21 |
Sex | |||||
Male | 314(69.5%) | 85(77.3%) | 60(67.4%) | 85(64.9%) | 84(68.9%) |
Female | 138(30.5%) | 25(22.7%) | 29(32.6%) | 46(35.1%) | 38(31.2%) |
Occupation | |||||
Service | 271(60.0%) | 65(59.1%) | 60(67.4%) | 83(63.4%) | 63(51.6%) |
Business | 61(13.5%) | 19(17.3%) | 8(8.99%) | 16(12.2%) | 18(14.8%) |
Housewife | 71(15.7%) | 13(11.8%) | 13(14.6%) | 21(16.0%) | 24(19.7%) |
Unemployed | 8(1.80%) | 1(0.91%) | 2(2.25%) | 2(1.53%) | 3(2.46%) |
Student | 24(5.3%) | 9(8.18%) | 5(5.62%) | 0 | 10(8.20%) |
Others | 17(3.80%) | 3(2.73%) | 1(1.15%) | 9(6.87%) | 4(3.28%) |
Education | |||||
0–5 years | 20(4.40%) | 9(8.18%) | 1(1.12%) | 3(2.29%) | 7(5.74%) |
6–10 years | 97(21.5%) | 28(25.5%) | 14(15.7%) | 13(9.92%) | 42(34.4%) |
11–12 years | 38(8.40%) | 9(8.18%) | 6(6.74%) | 7(5.34%) | 16(13.1%) |
Graduate | 107(23.7%) | 35(31.8%) | 18(20.2%) | 29(22.1%) | 25(20.5%) |
Post-graduate | 190(42.0%) | 29(26.4%) | 50(56.2%) | 79(60.3%) | 32(26.2%) |
Income | |||||
< 30,000 BDT | 116(25.7%) | 31(28.2%) | 15(16.9%) | 11(8.40%) | 59(48.4%) |
31,000–60,000 BDT | 154(34.1%) | 54(49.1%) | 33(37.1%) | 26(19.9%) | 41(33.6%) |
61,000–100,000 BDT | 70(15.5%) | 12(10.9%) | 27(30.3%) | 24(18.3%) | 7(5.74%) |
> 100,000 BDT | 112(24.8%) | 13(11.8%) | 14(15.7%) | 70(53.4%) | 15(12.3%) |
BMI category | |||||
Underweight | 16(3.50%) | 4(3.64%) | 3(3.37%) | 2(1.53%) | 7(5.74%) |
Normal | 249(55.1%) | 62(56.4%) | 47(52.8%) | 69(52.7%) | 71(58.2%) |
Overweight | 133(29.4%) | 27(24.6%) | 32(36.0%) | 41(31.3%) | 33(27.1%) |
Obese | 54(11.9%) | 17(15.5%) | 7(7.87%) | 19(14.5%) | 11(9.02%) |
Comorbidities | |||||
H/O diabetes | 46(10.2%) | 5(4.55%) | 5(5.62%) | 31(23.7%) | 5(4.10%) |
H/O hypertension | 54(12.0%) | 4(3.64%) | 11(12.4%) | 35(26.7%) | 4(3.28%) |
